NWSA vs RPRX · rev $9.03B vs P/E 15, rev $1.30B
NWSA (NWSA) versus Royalty Pharma Plc (RPRX) — a side-by-side from cached financials, not a winner call.
NWSA (NWSA) common stock.
Royalty Pharma Plc (RPRX) is a biotechnology company listed on US.
Latest reported NWSA revenue for 2026-06-30 was $9.03B. Net income was $573.0M. Revenue was up 328.1% from 2025-06-30 to 2026-06-30. NWSA currently screens at market cap $0.
Latest reported RPRX revenue for 2026-06-30 was $1.30B. Net income was $312.6M. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
NWSA currently screens at market cap $0. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
Not investment advice. Open the NWSA and RPRX stock pages for the full models.
Not investment advice.